“Feasible and effective administration of Bortezomib with Rituximab in children with relapsed/resistant B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A step toward the first line”

References

• Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress trough collaboration. JCO. 2015;33:2938–2948. doi: 10.1200/JCO.2014.59.1636.
   PubMed Web of Science ®Google Scholar
• Ghaderi S, Lie RT, Moster D, et al. Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway. Cancer Causes Control. 2012;23:1297–1305. doi: 10.1007/s10552-012-0007-x.
   PubMed Web of Science ®Google Scholar
• Goto H. Childhood relapsed acute lymphoblastic leukemia: biology and recent treatment progress. Pediatrics Int. 2015;57:1059–1066. doi: 10.1111/ped.12837.
   PubMed Web of Science ®Google Scholar
• Lovisa F, Zecca M, Rossi B, et al. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukemia. Br J Haematol. 2018;180:680–693. doi: 10.1111/bjh.15086.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322:1377–1380. doi: 10.1126/science.1164266.
   PubMed Web of Science ®Google Scholar
• Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012;120:285–290. doi: 10.1182/blood-2012-04-418640.
   PubMed Web of Science ®Google Scholar
• Kaspers GJL, Niewerth D, Wilhelm BAJ, et al. An effective modestly intensive re-induction regimen with bortezomib in relapse or refractory paediatric acute lymphoblastic leukemia. Br J Haematol. 2018;181:523–527. doi: 10.1111/bjh.15233.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112:3982–3988. doi: 10.1182/blood-2008-06-164129.
   PubMed Web of Science ®Google Scholar
• Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with Rituximab and Cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008;22:179–185. doi: 10.1038/sj.leu.2404959.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Romaguera JE, Feng L, et al. Phase II study of Bortezomib in combination with Cyclophosphamide and Rituximab for relapsed or refractory Mantle cell lymphoma. Oncologist. 2017;22(5):549–553. doi: 10.1634/theoncologist.2016-0328.
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ-BFM Study Group. JCO. 2009;27:377–384. doi: 10.1200/JCO.2008.17.6065.
   PubMed Web of Science ®Google Scholar
• Clavio M, Venturino C, Pierri I, et al. Combination of liposomal daunorubicin (DaunoXome), fludarabine and cytarabine (FLAD) in patients with poor risk acute leukemia. Ann Hematol. 2004; 83:696–703. doi: 10.1007/s00277-004-0927-y.
   PubMed Web of Science ®Google Scholar
• Conter V, Valsecchi MG, Parasole R, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123(10):1470–1478. doi: 10.1182/blood-2013-10-532598.
   PubMed Web of Science ®Google Scholar
• Miano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma. 2012;53(9):1693–1698. doi: 10.3109/10428194.2012.663915.
   PubMed Web of Science ®Google Scholar
• Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interaction with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58:13–23. doi: 10.1007/s00280-005-0135-z.
   PubMed Web of Science ®Google Scholar
• Messinger YH, Gaynon PS, Raetz E, et al. A Phase I study of bortezomib combined with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatric Blood Cancer. 2010;55(2):254–259.
   PubMed Web of Science ®Google Scholar
• Bertaina A, Vinti L, Strocchio L, et al. The combination of Bortezomib with chemotherapy to treat relapse/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017;176:629–636. doi: 10.1111/bjh.14505.
   PubMed Web of Science ®Google Scholar
• Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25:701–706. doi: 10.1097/CCO.0000000000000009.
   PubMed Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044–1053. doi: 10.1056/NEJMoa1605085.
   PubMed Web of Science ®Google Scholar
• Buitenkamp TD, Izraeli S, Zimmerman M, et al. Acute lymphoblastic leukemia in children with Down Syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70–77. doi: 10.1182/blood-2013-06-509463.
   PubMed Web of Science ®Google Scholar
• Von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II study of Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. JCO. 2016;34:4381–4389. doi: 10.1200/JCO.2016.67.3301.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2019;33:884–892. doi: 10.1038/s41375-018-0265-z.
   PubMed Web of Science ®Google Scholar
• Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232–2273. doi: 10.1007/s12325-017-0612-x.
   PubMed Web of Science ®Google Scholar